Last reviewed · How we verify
NCT06325930
A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6
Phase 1 trial testing [14C]-HU6 in Healthy in 8 participants. Completed in 7 May 2024.
7 May 2024
Quick facts
| Lead sponsor | Rivus Pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 26 March 2024 |
| Primary completion | 7 May 2024 |
| Estimated completion | 7 May 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- [14C]-HU6 — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Rivus Pharmaceuticals, Inc. — full company profile →
Who can join
Adults 18 to 55, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center, non-randomized, open-label Phase 1 study to characterize the absorption, metabolism, excretion, mass balance, pharmacokinetics (PK), safety and tolerability of HU6 following administration of a single dose of \[14C\]-HU6 in a fed state with a standard meal administered approximately 15 minutes prior to dosing.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06325930
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Rivus Pharmaceuticals, Inc. trials
Trials by the same sponsor.
- NCT07170189 — Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6 · Phase 1 · completed
- NCT06486558 — Relative Bioavailability Study of HU6 · Phase 1 · completed
- NCT05284617 — Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for S · Phase 2 · completed
- NCT05433506 — Safety and Pharmacokinetics of HU6 · Phase 1 · completed
- NCT04874233 — Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06325930 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rivus Pharmaceuticals, Inc.
- Last refreshed: 21 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06325930.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing